HC Wainwright Reiterates Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences (NASDAQ:XBIO)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports.

Xenetic Biosciences Price Performance

XBIO opened at $4.11 on Friday. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.20. The company has a market capitalization of $6.32 million, a price-to-earnings ratio of -1.54 and a beta of 2.25. The firm’s fifty day moving average price is $3.91 and its two-hundred day moving average price is $3.92.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The company had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. As a group, equities analysts anticipate that Xenetic Biosciences will post -1.01 EPS for the current year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.